Charcot-Marie-Tooth Disease Type 2S (CMT2S) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Charcot-Marie-Tooth disease type 2S (CMT2S) is an autosomal recessive axonal neuropathy characterized by the progressive weakening and wasting of distal muscles in the lower and upper limbs, typically manifesting in the first decade of life. Patients with CMT2S exhibit reduced reflexes and varying degrees of sensory impairment, primarily affecting the distal regions. The underlying cause of CMT2S is a mutation in the IGHMBP2 gene. Mutations in the IGHMBP2 gene can result in two distinct phenotypes: 1) severe SMARD1 (Spinal Muscular Atrophy associated with Respiratory Distress) or 2) milder CMT2S. Both conditions are rare and exhibit recessive inheritance patterns. The specific mutations within the IGHMBP2 gene determine whether patients develop SMARD1, characterized by autosomal recessive mutations in IGHMBP2 that are unrelated to the myelin protein MBP, or CMT2S, which leads to a gradual progression of weakness, muscle wasting, and sensory loss associated with an axonal neuropathy typical of CMT2 but without significant respiratory compromise. The most frequently observed phenotypes and symptoms associated with Charcot-Marie-Tooth Disease Type 2S include generalized hypotonia (reduced muscle tone throughout the body), scoliosis (abnormal sideways curvature of the spine), muscle weakness, delayed motor development, peripheral neuropathy (nerve damage affecting the peripheral nerves), gait disturbances, talipes equinovarus (clubfoot), respiratory insufficiency (inadequate respiratory function), areflexia (absence of reflexes), hyporeflexia (diminished reflexes).

·       The prevalence of CMT2S is estimated to be less than 1 in 1,000,000 worldwide.

Thelansis’s “Charcot-Marie-Tooth Disease Type 2S (CMT2S) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Charcot-Marie-Tooth Disease Type 2S (CMT2S) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Charcot-Marie-Tooth Disease Type 2S (CMT2S) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Charcot-Marie-Tooth Disease Type 2S (CMT2S) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Charcot-Marie-Tooth Disease Type 2S (CMT2S) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032